XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease with secondary programs focused on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.


Media and Videos

Scroll with arrows for additional content


Press Releases

XORTX Provides Overview and Announces $5 Million Financing to Advance Clinical Trials

Pivotal Registration Clinical Study with XRx-008 and Phase 2b Clinical Study withTMX-049 Planned in 2020 CALGARY, Alberta, April 29, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, confirms that the ...
Read More

Receive Press Releases by email

Please enable the javascript to submit this form

Investor Relations

Fact Sheet

Presentation

Read More